The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial. On November 21, 2025, the FDA approved pembrolizumab (Keytruda) and pembrolizumab and berahyaluronidase alfa-pmph ...
Panelists discuss how recognizing and mitigating common biases in real-world prostate cancer data helps clinicians interpret findings responsibly and apply them effectively in patient care. Panelists ...
In an interview at the 2025 LUGPA Annual Meeting, Stacy Loeb, MD, shared key takeaways from her session, “Current state of prostate cancer screening.” Loeb is a urologists at NYU Langone Health in New ...
Treatment intensification with ARPIs and chemotherapy has transformed mCSPC management, expanding the urologist's role in early treatment phases. Darolutamide is highlighted for its favorable safety ...
Beyond radioligands, Henderson points to a number of novel therapeutic categories under investigation. In this video, urologist Jonathan Henderson, MD, of Arkansas Urology in Little Rock, reflects on ...
Fast track designation accelerates development of [68Ga]Ga-DPI-4452 for ccRCC detection, enhancing FDA engagement and review processes. ITM-94, a gallium-68-radiolabeled PET agent, forms a theranostic ...
The ExactVu micro-ultrasound platform is noninferior to MRI in detecting clinically significant prostate cancer in biopsy-naïve men. Microultrasonography offers a cost-effective, in-office alternative ...
Gedatolisib and darolutamide combination targets PAM and AR pathways, potentially inducing a synergistic anti-tumor effect in mCRPC patients. Phase 1 trial with 38 patients showed promising safety, ...
Nanopath's assay for cUTIs has received FDA breakthrough device designation, indicating its potential to significantly advance UTI diagnosis. The assay aims to deliver molecular results in 15 minutes, ...
The 2025 European Society for Medical Oncology (ESMO) Congress, in Berlin, Germany, delivered several noteworthy data readouts in genitourinary oncology. Prostate cancer in particular saw a wave of ...
Celeste Kirschner, CAE, MHSA, outlines the most pressing challenges facing independent urology practices today. "I think MRI has really been perhaps the most transformative development in the realm of ...
Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback